MaxCyte Investor Presentation Deck

Value Creation from SPLs BT tit Licensing deals include significant development milestones and high-value participation in future commercial success of partners Potential value of pre-commercial (clinical development) milestones from SPLs: ~$2B Sales-based payments upon partner's product commercialization Recurring revenues from lease of instruments and sales of single-use disposables that grow with program success Milestone revenue is MaxCyte's highest growth revenue stream **Casebia/CRISPR's SPL partnership (signed in 2017) included the rights to use MaxCyte's technology in the development of exa- cel (formerly known as CTX001). As announced in the press release on September 28th, 2022, Vertex has signed an SPL agreement with MaxCyte - Vertex has obtained the clinical and commercial rights to use MaxCyte's technology for the development of exa-cel (formerly known as CTX001). 6 Cumulative Potential Pre-CML Milestones Potential Value of Pre-Commercial Milestones: ~$2B USD ** CASEBIA THERAPEUTICS 2017 PRECISION BIOSCIENCES CRISPRI THERAPEUTICS 2018 KSQ V VOR BIOPHARMA editas MEDICINE Beam THERAPEUTICS Kite AGILEADC invios INNOVATIVE IMMUNO-ONCOLOGY CARIBOU BIOSCIENCES™ Allogene nkarta THERAPEUTICS Sana Biotechnology M MaxCyte CO celularity curamys 2020 2021 2019 Graph is provided for illustrative purposes only. VERTEX LG Chem MYELCID % INTIMA BIOSCIENCE 2022 prime medicine_ VITTORIA biotherapeutics Lyell WALKING FISH THERAPEUTICS catamaranBIO 2023 © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation